Jump Financial LLC Invests $828,000 in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)

Jump Financial LLC acquired a new position in shares of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 86,199 shares of the company's stock, valued at approximately $828,000. Jump Financial LLC owned approximately 0.12% of Fusion Pharmaceuticals as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the business. Signaturefd LLC grew its position in shares of Fusion Pharmaceuticals by 883.0% in the 4th quarter. Signaturefd LLC now owns 2,949 shares of the company's stock valued at $28,000 after acquiring an additional 2,649 shares during the period. New York State Common Retirement Fund bought a new position in shares of Fusion Pharmaceuticals in the 4th quarter valued at about $64,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Fusion Pharmaceuticals in the 4th quarter valued at about $80,000. Forefront Analytics LLC lifted its stake in shares of Fusion Pharmaceuticals by 67.8% during the 3rd quarter. Forefront Analytics LLC now owns 33,685 shares of the company's stock worth $88,000 after buying an additional 13,610 shares during the last quarter. Finally, abrdn plc acquired a new stake in shares of Fusion Pharmaceuticals during the 4th quarter worth about $209,000. Institutional investors own 72.85% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on FUSN shares. William Blair cut shares of Fusion Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research note on Tuesday, March 19th. Brookline Capital Management cut shares of Fusion Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Tuesday, March 19th. Jefferies Financial Group reiterated a "hold" rating and issued a $21.00 price objective (up previously from $10.00) on shares of Fusion Pharmaceuticals in a research note on Tuesday, March 19th. Wedbush cut shares of Fusion Pharmaceuticals from an "outperform" rating to a "neutral" rating and set a $24.00 price objective for the company. in a research note on Tuesday, March 19th. Finally, Raymond James reiterated a "market perform" rating on shares of Fusion Pharmaceuticals in a research note on Tuesday, March 19th. Thirteen analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $20.25.

Fusion Pharmaceuticals Price Performance

Shares of Fusion Pharmaceuticals stock traded up $0.02 during midday trading on Monday, hitting $21.53. 342,824 shares of the company traded hands, compared to its average volume of 1,694,406. The stock has a market cap of $1.83 billion, a price-to-earnings ratio of -15.16 and a beta of -0.69. The company has a debt-to-equity ratio of 0.21, a quick ratio of 10.64 and a current ratio of 10.64. The firm's fifty day moving average price is $20.20 and its 200-day moving average price is $12.50. Fusion Pharmaceuticals Inc. has a 12 month low of $2.31 and a 12 month high of $21.58.

Fusion Pharmaceuticals (NASDAQ:FUSN - Get Free Report) last announced its quarterly earnings results on Wednesday, March 20th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.05). Fusion Pharmaceuticals had a negative net margin of 4,136.55% and a negative return on equity of 48.74%. As a group, sell-side analysts forecast that Fusion Pharmaceuticals Inc. will post -1.44 earnings per share for the current year.

About Fusion Pharmaceuticals

Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor.